Technology Development and Transfer Platform

The Technology Development and Transfer Platform (PDTT-CIBERES) is a transversal CIBERES instrument which seeks to promote the technological research and development work of our groups in the field of respiratory medicine, as well as to promote its clinical translation and business transfer.

The technological fields of the PDTT include medical teams, information technologies and communication (ITC), technology-based healthcare services, pharmacology, biotechnology, nanobiotechnology and bioinformatics. The platform does its work in close coordination with the Research Results Transfer Offices (OTRI) or Innovation Units of the institutions forming part of the CIBERES consortium.

The PDTT is a unified channel for supply and demand in matters of technology transfer and innovation for the CIBERES, a consortium with its own legal personality representing the largest association of specialists in excellence in the national respiratory sphere working jointly in strategic projects for most diseases of the respiratory system.

The PDTT is thus in charge of coordinating and managing the information that comes in from all the agents involved in the transfer process, researchers, companies, OTRIS/Innovation Units, institutions financing innovation, industrial property agents, associations etc.

The objectives of the PDTT are:

  • To increase the potential and visibility of the technological work done by the CIBERES.
  • To guarantee an operative fast and effective response to the entire process for transferring to researchers and the CIBERES.
  • To protect the intellectual property and rights of the CIBERES and its researchers.
  • To ensure good coordination and communication between the different agents in the CIBERES transfer field.

The platform undertakes all the measures required to comply with these objectives and to succeed in speeding up the transfer of knowledge and technology from the research environment to the business setting.

If you would like to get in touch with us please do so at: transferencia@ciberes.org

Technology supply

In this area you will be able to consult our technology supply and demand available for cooperation with business. For any further information, request or enquiry please get in touch with us at transferencia@ciberes.org.We are open to different types of cooperation.

Technology offered by the CIBERES

1. New antibiotics. The only compounds addressing DNA Topoisomerase 1

The Seconeolitsine and N-methyl-seconeolitsine compounds work on S. pneumoniae and other bacteria, at low µM concentrations, in multi-resistant bacteria with greater protection action than that of fluoroquinolones.

2. New families of compounds for use in the treatment of inflammatory diseases occurring with cell apoptotic and fibrotic processes

The compounds are useful for preparing a pharmaceutical composition for treatment of inflammatory diseases occurring with cell apoptotic and fibrotic processes such as: sepsis, sepsis-induced ALI, sepsis-induced ARDS, endotoxic shock, endotoxemia, traumatic lesion and cell damage.

3. New broad-spectrum and enhanced activity enzybiotics

Sequence and synthesis of polypeptides with greater binding capacity and greater activity against pneumococci and other Gram-positive and Gram-negative bacteria.

4. Fast method for evaluating whether different samples of M. Tuberculosis originate in the same clone and resistances to rifampicin and isoniazid

Based on IS6110 (Gold standard), this provides fast (a few hours) automated, standardised and reproducible results. The extensive use of this technology will enable greater control of tuberculosis. The technology also identifies resistances to rifampicin and isoniazid and can be extended to other bacteria which contain specific IS.

5. Set of miRNAs as markers for diagnosis of Diffuse Alveolar Damage (DAD)

Set of miRNAs whose expression identifies the presence of DAD in patients’ serum with a specificity over 75%. The method could become an important tool for diagnosing DAD in health conditions with a high risk of developing this and a tool for confirming Acute Respiratory Distress Syndrome (ARDS) for patients who are already clinically suspected to have this.

6. Nanoparticle for cancer therapies

The invention refers to micelles containing an iron-oxide UCNP or metal core, surrounded by an organic layer and covered with glycoside-derived compounds with anti-tumoral activity. These nanoparticles enable solubility in water of the insoluble compounds and the use of a magnetic field for purposes of concentrating these in a specific area.

7. Test for predicting the response of patients with hypertension resistant to treatment with constant positive airway pressure (CPAP)

A test based on a set of miRNAs whose expression in plasma can predict the positive response of patients with hypertension resistant to treatment by CPAP. This method enables identification with high sensitivity and specific values of patients with resistant hypertension who can positively benefit from treatment with CPAP.

8. Bimodal liposomes for PET and optical imaging of tumours

These bimodally marked liposomes enable images to be obtained by means of PET and intraoperative optics. This means that both the biodistribution and the accomplishment of the objective in liposomal therapy can be viewed non-invasively. These liposomes have a long circulation time as well as high stability. Apart from this, these nanoparticles are accumulated in areas of vasculature with leaks due to the effect of enhanced permeability and retention (EPR). These liposomes are useful for detecting and delineating malignant growth, inflammation and infection in different diseases and are of great value in a theranostic platform.

9. New control system for oxygenotherapy

The new device offers a variable flow of oxygen depending on physical work and other physiological parameters. It has a wireless design compatible with telemetry, is easy to use and portable. It anticipates the oxygen demand before signs of oxygen desaturation are noticed. Validated for patients with idiopathic pulmonary fibrosis (IPF).